Search results for: RIMONABANT

• In vivoevaluation of the CB1allosteric modulator LDK1258 reveals CB1-receptor independent behavioral effects

  Publication

  • T. Olszewska
  • M. Mohammed
  • G. Donvito
  • L. Moncayo
  • A. Swafford
  • J. Poklis
  • R. Grauer
  • B. Ignatowska-Jankowska
  • D. A. Kendall
  • D. Lu
  • A. H. Lichtman

  - PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR - Year 2020

  In the present study, we examined whether LDK1258, which produces strong CB1receptor allosteric effects ininvitroassays, would elicitin vivoeffects consistent with allosteric activity. In initial studies, LDK1258 reducedfood consumption and elicited delayed antinociceptive effects in the chronic constrictive injury of the sciaticnerve (CCI) model of neuropathic pain, which unexpectedly emerged 4 h post-injection. UPLC-MS/MS analysisquantified...

  Full text to download in external service

• (4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl)Methanone Hydrochloride (LDK1229): A New Cannabinoid CB1 Receptor Inverse Agonist from the Class of Benzhydryl Piperazine Analogs

  Publication

  • M. M. Mahmoud
  • T. Olszewska
  • H. Liu
  • D. M. Shore
  • D. P. Hurst
  • P. H. Reggio
  • D. Lu
  • D. A. Kendall

  - MOLECULAR PHARMACOLOGY - Year 2015

  Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated to be anorectic antiobesity drug candidates. However, the first generation of CB1 inverse agonists, represented by rimonabant (SR141716A), otenabant, and taranabant, are centrally active, with a high level of psychiatric side effects. Hence, the discovery of CB1 inverse agonists with a chemical scaffold distinct from these holds promise for developing...

  Full text to download in external service